argenx NV ADR (ARGX)vsElicio Therapeutics Inc. (ELTX)
ARGX
argenx NV ADR
$981.33
+0.38%
HEALTHCARE · Cap: $58.31B
ELTX
Elicio Therapeutics Inc.
$1.56
-4.29%
HEALTHCARE · Cap: $43.08M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ELTX
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.3%
Fair Value
$2552.01
Current Price
$981.33
$1570.68 discount
Intrinsic value data unavailable for ELTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 33 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Safe zone — low bankruptcy risk
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 182.4x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : ELTX
ELTX has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ELTX
The primary concerns for ELTX are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.78 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ELTX is a value play — different risk/reward profiles.
ELTX carries more volatility with a beta of 2.00 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 17/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Elicio Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002, leverages a proprietary Amphiphilic TLR9 Agonist to elicit robust immune responses against various cancer types, aiming to enhance patient outcomes. By concentrating on personalized cancer vaccines and groundbreaking immunotherapeutic approaches, Elicio Therapeutics is uniquely positioned to tackle significant unmet clinical needs in oncology, while advancing its compelling pipeline through rigorous clinical trials that could redefine the standard of cancer care.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?